Clinical Trial Update: HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 trial evaluating an HLA-A2-restricted glioma antigen-peptide vaccine with Poly-ICLC in recurrent WHO Grade II gliomas (astrocytoma, oligoastroc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Oligoastrocytoma
• Oligodendroglioma

Drugs mentioned

• HLA-A2-Restricted Glioma Antigen-Peptide Vaccine (HLA-A2-restricted glioma antigen peptide vaccine)
• Poly-ICLC (Hiltonol) (polyinosinic-polycytidylic acid stabilized with poly-L-lysine)

Snippet

Sponsor: Ian F. Pollack, M.D. | Conditions: Astrocytoma, Oligoastrocytoma | EARLY_Phase 1 | Status: COMPLETED